Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn’s Disease and Effects of Natalizumab Therapy
- 1 November 2015
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 13 (11) , 1919-1925
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Anti-JC Virus Antibody Prevalence in Canadian MS PatientsCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2014
- Novel pathophysiological concepts of inflammatory bowel diseaseJournal of Gastroenterology, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunitiesInflammatory Bowel Diseases, 2006
- Natalizumab Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabNew England Journal of Medicine, 2005
- Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.2005
- Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s diseaseGastroenterology, 2004
- Prevalence of BK virus and JC virus in peripheral blood leukocytes and normal arterial walls in healthy individuals in ChinaJournal of Medical Virology, 2003
- Prevalence Rate and Age of Acquisition of Antibodies against JC Virus and BK Virus in Human SeraMicrobiology and Immunology, 1982